Beauty Health (SKIN)
NASDAQ:SKIN
Want to see SKIN full AI Analyst Report?
SKIN Stock Chart & Stats
$0.91
-$0.07(-3.95%)
At close: 4:00 PM EST
$0.91
-$0.07(-3.95%)
Day’s Range― - ―
52-Week Range$0.55 - $2.69
Previous CloseN/A
Volume138.49K
Average Volume (3M)1.04M
Market Cap
$82.13M
Enterprise Value$263.08M
Total Cash (Recent Filing)$204.40M
Total Debt (Recent Filing)$367.20M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Aug 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding129,600,040
10 Day Avg. Volume926,645
30 Day Avg. Volume1,036,656
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.88
Price to Sales (P/S)0.58
P/FCF Ratio4.72
Enterprise Value/Market Cap3.20
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit1.37
Enterprise Value/Ebitda6.14
Forecast
1Y Price Target
$1.50Price Target Upside64.84% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.15
Revenue Forecast (FY)$289.47M
Bulls Say, Bears Say
Bulls Say
High Product-level Margins And Cash GenerationSustained high gross margins and positive trailing‑twelve‑month operating and free cash flow indicate durable product economics from the razor‑and‑blades model. This cash generation supports reinvestment, working capital and near‑term debt servicing, reducing reliance on equity financing.
Growing Installed Base With Meaningfully Lower ChurnA larger, stickier installed base crystallizes recurring consumables revenue and raises lifetime customer value. Reduced device churn signals improved provider retention and utilization, which underpins more predictable consumables sales and steadier cash flow over multiple quarters and years.
Operational Discipline, Product Innovation And Board RefreshManagement has cut costs, maintained adjusted EBITDA guidance and strengthened governance while progressing product and clinical initiatives. That combination increases odds of commercial recovery, enhances strategic oversight, and supports sustainable margin improvement as new products and leadership regain momentum.
Bears Say
Very High Leverage And Limited Balance‑sheet FlexibilityA debt-laden balance sheet severely constrains financial flexibility; high leverage raises refinancing and interest risks, limits ability to invest in growth or absorb cyclical revenue shortfalls, and means a greater portion of cash flow must go to debt servicing rather than product development or marketing.
Top-line Pressure And Weak Device PlacementsFalling device placements and declining consumables in key regions reflect longer capital cycles, distributor transitions and intensifying competition. Because consumables growth depends on installed systems and treatments, persistent placement weakness directly slows recurring revenue expansion and prolongs the path to stronger cash generation.
Nasdaq Bid-price Notice Creates Listing And Financing RiskA formal bid‑price deficiency notice raises the prospect of a reverse split, delisting or investor reluctance. Such outcomes can hamper access to equity capital, distract management, depress liquidity and complicate refinancing of upcoming maturities, exacerbating balance‑sheet strain during a recovery period.
Beauty Health News
SKIN FAQ
What was Beauty Health’s price range in the past 12 months?
Beauty Health lowest stock price was $0.55 and its highest was $2.69 in the past 12 months.
What is Beauty Health’s market cap?
Beauty Health’s market cap is $82.13M.
When is Beauty Health’s upcoming earnings report date?
Beauty Health’s upcoming earnings report date is Aug 11, 2026 which is in 61 days.
How were Beauty Health’s earnings last quarter?
Beauty Health released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.074 by $0.024.
Is Beauty Health overvalued?
According to Wall Street analysts Beauty Health’s price is currently Undervalued.
Does Beauty Health pay dividends?
Beauty Health does not currently pay dividends.
What is Beauty Health’s EPS estimate?
Beauty Health’s EPS estimate is -0.02.
How many shares outstanding does Beauty Health have?
Beauty Health has 129,600,040 shares outstanding.
What happened to Beauty Health’s price movement after its last earnings report?
Beauty Health reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.074. Following the earnings report the stock price went down -36.264%.
Which hedge fund is a major shareholder of Beauty Health?
Currently, no hedge funds are holding shares in SKIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beauty Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (64.84% Upside)
$1.50 (64.84% Upside)
Hedge Fund Trend
Increased
By 319.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.85%
12-Months-Change
Fundamentals
Return on Equity
-9.41%
Trailing 12-Months
Asset Growth
-29.77%
Trailing 12-Months
Company Description
Beauty Health
The Beauty Health Company is an international enterprise focused on the conceptualization, development, production, promotion, and distribution of advanced aesthetic equipment and beauty solutions. Its leading offering is HydraFacial, a renowned skincare system that works to revitalize the complexion through a multi-step process: deep cleansing, gentle exfoliation, impurity extraction, active ingredient infusion, and intensive hydration, all powered by proprietary blends and specialized serums. Beyond this, their portfolio encompasses Syndeo, a sophisticated HydraFacial Delivery System designed to optimize every phase of the treatment and allow practitioners to tailor experiences to individual client preferences. They also provide the HydraFacial Nation App, a digital tool enabling users to gain insights into their skin's condition, explore various treatment options, and track their progress over subsequent sessions. Another key product is Keravive, a specialized treatment dedicated to fostering scalp health. The company was established in 1997 and maintains its corporate headquarters in Long Beach, California.
SKIN Company Deck
SKIN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: operational and financial discipline produced a notable EBITDA beat, margin expansion, improved installed base metrics, and strong liquidity, but top-line performance remains pressured with declining sales, softer device placements, and structural macro/competitive headwinds. Management is taking concrete commercial and product actions and maintained EBITDA guidance while trimming revenue expectations, positioning 2026 as an execution/stabilization year with recovery expected in 2027.View all SKIN earnings summariesSKIN Stock 12 Month Forecast
Average Price Target
$1.50
▲(64.84% Upside)
Technical Analysis
Ownership Overview
15.74% Insiders
11.13% Mutual Funds
23.13% Other Institutional Investors
42.39% Public Companies and
Individual Investors